By Gregory Mannix, Vice President International Business Development, LSN
At last month’s Healthtech Partnering Week, McDermott Will & Emery hosted a workshop focused on the all-important Term Sheet. A stellar panel of experts shared their own vast experience in this area, not only from a legal perspective, but from the perspective of a fundraising entrepreneur and an investor. Not surprisingly, this was among the best-attended panels at RESI, therefore, we are sharing the recording with our extended community.
If you have any questions about Term Sheets, feel free to reach out to MWE’s Angus McQuilken.
Nancy Briefs, President & CEO, AltrixBio, Inc.
Strategic business leader with extensive experience creating value, driving strategy and launching product commercialization in diverse life science companies. Deep general management and fundraising expertise having raised over $500 M in equity including IPO. Innovative, collaborative and entrepreneurial, strong communicator and tenacious. Energized by turning innovation into commercial reality, working with creative scientists, and communicating value to partners and investors.
David Hendren, Managing Director, Augmentum Ventures
David Hendren has extensive experience launching, financing, and building successful ventures from incubation to exit, with particular expertise in healthcare, biomedical technology, digital health, and related technology and service areas. He has deep knowledge and broad perspective from 25+ years in leadership roles on virtually all sides of the table, including VC, entrepreneur, CEO, board member/chair, advisor, consultant, and counsel. David has led, co-invested and executed deals with leading firms and strategics, with exits including IPO, M&A, and technology licensing transactions. In operating, board, and advisory roles, David has been central to identifying opportunity, building teams, formulating strategy, securing capital, developing business and strategic alliances, and driving successful exits to harvest value for stakeholders.
John Demeter, General Counsel, Khosla Ventures
John is the General Counsel at Khosla Ventures. He joined Khosla in 2016 and has been working with investors and entrepreneurs since 2007. Prior to joining Khosla, John spent nine years at WilmerHale where he represented investors and entrepreneurs in hundreds of financing and acquisition transactions. Given his experience, John has also served as an adjunct professor and guest lecturer at numerous Bay Area law schools on the topic of venture capital transactions.
Prior to attending law school, John held sales and marketing positions at two Bay Area venture-backed companies, had an ever so brief career in local radio, and spent a year working at his family’s commercial transportation business.
John received CORe certification from Harvard Business School Online, his JD cum laude from University of San Francisco School of Law and his Bachelor of Arts in Communications from Boston College. A Bay Area native, John is passionate about the local sports teams. He lives in San Francisco with his wife, four young children and loyal pack of dogs.
Mark Mihanovic, Partner, McDermott Will & Emery
Mark J. Mihanovic, head of the Firm’s California Corporate group and head of the Emerging Companies/Venture Capital group, focuses his practice primarily in the areas of corporate finance and mergers and acquisitions. He represents companies in a broad range of industries, with a particular emphasis on technology, life science and health care companies. Mark serves as corporate liaison partner in the Firm’s strategic alliance with MWE China Law Offices based in Shanghai. Mark serves as lead counsel on behalf of issuers and underwriters in public offerings and private placements (including private investments in public equities (PIPEs)) of equity and debt securities. He handles stock and asset acquisitions, divestitures, mergers, proxy fights and joint ventures and has had primary oversight responsibility for the regional and worldwide acquisition programs of multiple clients. Mark represents early-stage companies in connection with formation and organizational issues and venture capital and other financings and has also represented investors in complex venture capital transactions involving equity and debt. Mark has substantial experience advising corporate boards of directors and management regarding fiduciary duties (including in connection with potential change in control transactions and consideration of “poison pill” stockholders rights plans) and corporate governance issues. He assists publicly traded companies with their Securities and Exchange Commission filings and other securities compliance matters. He also advises investment banks on securities compliance issues and in acting as financial adviser and delivering fairness opinions in the context of acquisitions and restructurings.
Aroma Sharma, Partner, McDermott Will & Emery
Aroma Sharma focuses her practice on a wide range of corporate and transactional matters, acting predominantly for private and emerging companies. Aroma has advised clients on mergers and acquisitions, debt and equity financing, corporate and equity restructuring and recapitalizations and joint ventures in various industries, including technology and health and life sciences. She also advises clients regularly on general corporate and corporate governance matters. Aroma also has experience working on cross-border transactions, including business’ international expansion into new territories.
Aroma regularly serves as primary outside counsel for clients. She understands the importance of knowing a client’s business, and completed a secondment with a large, multi-national accounting and advisory firm, assisting with drafting and negotiating commercial transactional agreements.
Aroma was also a fellow in Entrepreneurship, Social Entrepreneurship & Innovation at NYU School of Law and has a special interest in working with social enterprises and sustainable businesses.
